A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer.
Stereotactic body radiation therapy (SBRT) is a new treatment modality. To confirm the safety and efficacy, the Radiation Therapy Study Group of the Japan Clinical Oncology Group (JCOG) has started a phase II study of SBRT for stage IA non-small cell lung cancer (JCOG 0403). This study is ongoing with a strict quality control and quality assurance program, and the results will indicate whether a future phase III trial comparing SBRT with surgery is warranted. In addition, international collaboration will be critical to establish the role of SBRT in the treatment of lung cancer.